Immuno-Oncology Program

Size: px
Start display at page:

Download "Immuno-Oncology Program"

Transcription

1 Immuno-Oncology Program 2018

2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, but are not limited to, financial guidance for full year 2017 as it relates to revenues, operating expenses, and year end cash balances; the design of clinical trials and expected timing for release of data; the anticipated clinical development milestones and other potential value drivers in the future; the expected benefits of the collaboration with Pfizer, the expanded capability of Sangamo s technologies; the benefits of rebranding and reorganization, the research and development of novel gene-based therapies and the application Sangamo s ZFP technology platform to specific human diseases; corporate partnerships; and the potential of Sangamo s genome editing technology to treat genetic diseases. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo s therapeutics, the ability to establish strategic partnerships and our ability to control expenses and achieve our milestones that generate revenues under our agreements. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo s operations and business environments. These risks and uncertainties are described more fully in Sangamo s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this presentation are made as of the date hereof, and Sangamo undertakes no duty to update such information except as required under applicable law. 2

3 We are committed to translating ground-breaking science into genomic therapies that transform patients lives 3

4 Sangamo is investing across four technological platforms for genomic medicines Gene Therapy Genome Editing Cell Therapy Gene Regulation 4

5 Clearly defined scope of the Kite-Gilead deal Strategic Collaboration in Oncology T cells and NK cells Ex Vivo genome editing (ZFNs and AAV) Cell Therapy Oncology CARs, TCRs, and NKRs directed to tumor antigens Autologous and allogeneic products Solid and liquid tumor types 5

6 Kite-Gilead deal economics $150M $3.01B Upfront payment $300M in potential per product milestone payments, up to 10 times Cell Therapy Oncology Tiered royalties on net sales 6

7 Product portfolio diversified across therapeutic area and technology Therapeutic Area Research Preclinical Phase 1/2 Phase 3 Collaborator Inherited Metabolic Diseases MPS I (SB-318) MPS II (SB-913) Fabry Disease (ST-920) Hematology Hemophilia A (SB-525) Hemophilia B (SB-FIX) Beta-thalassemia (ST-400) Sickle Cell Disease (BIVV-003) CNS Diseases Tauopathies ALS/FTLD - C9ORF72 Huntington s Disease Oncology Autologous and Allogeneic CAR/TCR/NKR Immunology Undisclosed Autoimmune Disease Targets Investigator Sponsored Clinical Research HIV (T cell and Stem Cell) Gene Therapy Genome Editing Cell Therapy Gene Regulation 7

8 ZFNs: The platform of choice for therapeutic genome editing T A C C C A A C G C G A A T T A T G A T G G G T T G C G C T T A A T A C ZFN T G C G C T T A A C G C A T G G G T A C G C G A A T T G C G T A C C C A ZFPs Precision Target any desired nucleotide in the genome ZFPs ZFN ZFNs Efficiency Level of modification at the desired target nucleotide Specificity Edit the targeted nucleotide without editing elsewhere in the genome 8

9 T-cell Receptor Expression We can reliably hit >90% gene editing efficiency in T-cells 93% Double KO 91% Targeted Insertion (TI) HLA Expression Transgene Expression Precise KO at TRAC and B2M loci with no detectable off-target activity Precise TI at TRAC locus with no detectable off-target activity 9

10 Off-the-shelf T cell therapy: eliminating TCR and/or HLA on CAR + T cells Healthy donor T cells Patient 10

11 Manufacturing allogeneic T-cell therapies with ZFNs cgmp Manufacturing Facility HLA knock-out TCR knock-out Targeted insertion of CAR gene Apheresis (Healthy Donor) Isolate T-cells from a healthy donor s blood T-cell Manufacturing Transient, non-viral delivery of ZFN mrna to manufacture universal CAR-T cells via singlestep, multiplexed gene editing Harvest & Storage Universal CAR-T cells are harvested, cryo-preserved and stored in a secure cell bank Infusion (Patients) Universal, off-the-shelf CAR-T cells are infused into new patients, on-demand 11

12 Allogeneic cell therapy production: high efficiency is critical for single-step multiplexed genome editing 1 KO + 1 KO + 1 TI Compounded Efficiency Very High 99% x 99% x 99% = 97% High 90% x 90% x 90% = 73% Medium 70% x 70% x 70% = 34% Low 50% x 50% x 50% = 13% 12

13 Cell therapy platform: simultaneous multiplex editing efficiencies with 3x ZFN KO + 1x targeted integration % EDITING POTENTIAL APPLICATION: Universal T cells with checkpoint gene knock-out % 9 6 % 9 3 % 9 1 % SINGLE STEP EDITING ZFN Knock-out TCR (TRAC) HLA-class I (β2m) CISH (checkpoint gene) Targeted Insertion GFP (into TRAC) T C R - 2 M - C I S H - G F P + 76% of cells have all 4 edits KO: TCR, β2m and CISH; TI: GFP (TRAC) 13

14 Harnessing the precision, efficiency and specificity of ZFNs for autologous and allogeneic cell therapy products for oncology Autologous / Allogeneic Cell Therapy Strategy Targeted integration of CAR/TCR gene High editing efficiency (>90%) significantly reduces manufacturing cost >90% endogenous TCR knock-out (KO) eliminates GvHD >90% HLA KO eliminates host immune response to modified cells Precision of ZFNs better safety profile expected vs comparative therapies in development Strategic Advantages 90% editing efficiency (~2x other gene editing technologies) Consistent transduction efficiency and low risk of insertional mutagenesis vs retrovirus-based cell modification Highly efficient, targeted integration at TRAC locus for better regulation of CAR-T construct under endogenous promoter Precise HLA/TCR gene KO for allogeneic cell therapy development 14

15 Thank you.

Q4 and Full Year 2017 Conference Call. February 22, 2018

Q4 and Full Year 2017 Conference Call. February 22, 2018 Q4 and Full Year 2017 Conference Call February 22, 2018 Agenda Welcome McDavid Stilwell VP, Corporate Communications and Investor Relations Q4 2017 and Full Year Review and Recent Highlights Dr. Sandy

More information

Corporate Presentation. March 2018

Corporate Presentation. March 2018 Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation

More information

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements

More information

Sumiti Jain. [Poster #2003, Tuesday February 13 th ] February 12 th, 2018

Sumiti Jain. [Poster #2003, Tuesday February 13 th ] February 12 th, 2018 Dual Knock-Out of Endogenous T-Cell Receptor and HLA-Class I using Zinc Finger Nucleases with Site-Specific Insertion of a CD19 CAR: Implications for Allogeneic T Cell Therapy Sumiti Jain February 12 th,

More information

SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CNS Gene Regulation Platform

CNS Gene Regulation Platform CNS Gene Regulation Platform 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation

More information

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements

More information

Sangamo BioSciences Reports First Quarter 2014 Financial Results

Sangamo BioSciences Reports First Quarter 2014 Financial Results May 6, 2014 Sangamo BioSciences Reports First Quarter 2014 Financial Results Partnership with Biogen Idec and Recent Follow-on Financing Enhance Cash Position RICHMOND, Calif., May 6, 2014 /PRNewswire/

More information

Sangamo BioSciences Reports Third Quarter 2014 Financial Results

Sangamo BioSciences Reports Third Quarter 2014 Financial Results October 22, 2014 Sangamo BioSciences Reports Third Quarter 2014 Financial Results RICHMOND, Calif., Oct. 22, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its third quarter

More information

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy April 24, 2017 Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics,

More information

Sangamo BioSciences Reports Third Quarter 2013 Financial Results

Sangamo BioSciences Reports Third Quarter 2013 Financial Results October 23, 2013 Sangamo BioSciences Reports Third Quarter 2013 Financial Results Recent Financing Enhances Cash Position RICHMOND, Calif., Oct. 23, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq:

More information

Q Earnings and Corporate Developments. October 31, 2018

Q Earnings and Corporate Developments. October 31, 2018 Q3 2018 Earnings and Corporate Developments October 31, 2018 1 Intellia Therapeutics Legal Disclaimers This presentation contains forward-looking statements of Intellia Therapeutics, Inc. ( Intellia )

More information

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements

More information

ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities

ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities August 9, 2016 ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities Company to Host Conference Call at 4:30 PM ET Today BOSTON, Aug. 09, 2016 (GLOBE NEWSWIRE)

More information

RXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals

RXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Investor Presentation

Investor Presentation 1 Revolutionizing Medicine A Breakthrough Scientific Discovery Curative Treatments Targeting the Underlying Genetic Cause of Disease Investor Presentation 2018 Intellia Therapeutics Legal Disclaimers This

More information

CMC Considerations for Manufacturing of CAR T-Cell Product

CMC Considerations for Manufacturing of CAR T-Cell Product CMC Considerations for Manufacturing of CAR T-Cell Product November 14, 2017 Joann M. Parker, R.Ph, M.S. Regulatory Global CMC; Pfizer Inc Session: New Modalities for Cancer Moonshot: Unique Regulatory,

More information

(212) Cellectis Media Contact: Philippe Valachs +33(0)

(212) Cellectis Media Contact: Philippe Valachs +33(0) For immediate release: June 18, 2014 Pfizer Media Contact: Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com Cellectis Media Contact: Philippe Valachs +33(0)1 81 69 16 00 media@cellectis.com Pfizer

More information

Jefferies 2017 Global Healthcare Conference. Dr Sandy Macrae CEO June 9, 2017

Jefferies 2017 Global Healthcare Conference. Dr Sandy Macrae CEO June 9, 2017 Jefferies 2017 Global Healthcare Conference Dr Sandy Macrae CEO June 9, 2017 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions

More information

Cell and Gene Therapy Catapult clinical trials database

Cell and Gene Therapy Catapult clinical trials database Cell and Gene Therapy Catapult clinical trials database Executive summary The number of cell and gene therapy clinical trials in the UK continues to increase with 85 ongoing trials at present, representing

More information

2016 Annual Meeting of Stockholders. October 20, 2016

2016 Annual Meeting of Stockholders. October 20, 2016 2016 Annual Meeting of Stockholders October 20, 2016 Safe Harbor Statement Statements herein relating to future financial or business performance, conditions or strategies and other financial and business

More information

The Cell and Gene Therapy Catapult UK clinical trials database

The Cell and Gene Therapy Catapult UK clinical trials database The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)

More information

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose. Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose. Pharmaceutical products have been historically made of purified

More information

Gene Therapy Clinical Pipeline

Gene Therapy Clinical Pipeline Gene Therapy Clinical Pipeline Sector Overview Lyndsey Scull Vice President, Communications Alliance for Regenerative Medicine 2 About ARM International advocacy organization Dedicated to realizing the

More information

Building a Full-Spectrum Genome Editing Company

Building a Full-Spectrum Genome Editing Company Building a Full-Spectrum Genome Editing Company 2018 1 Intellia Therapeutics Legal Disclaimers This presentation contains forward-looking statements of Intellia Therapeutics, Inc. ( Intellia ) within the

More information

The Cell and Gene Therapy Catapult UK clinical trials database

The Cell and Gene Therapy Catapult UK clinical trials database The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)

More information

Genome editing: clinical applications FYODOR URNOV

Genome editing: clinical applications FYODOR URNOV Genome editing: clinical applications FYODOR URNOV Double-strand break repair D. Carroll Genome-Editing Nucleases Zinc Finger Nucleases (ZFNs) TALE Nucleases (TALENs) Sangamo / Biogen Cellectis / Pfizer

More information

AdenoVerse Platform for Translational Development of Innovative Gene and Cell Therapies Cell & Gene Therapy World January 18, 2017

AdenoVerse Platform for Translational Development of Innovative Gene and Cell Therapies Cell & Gene Therapy World January 18, 2017 AdenoVerse Platform for Translational Development of Innovative Gene and Cell Therapies Cell & Gene Therapy World Douglas E. Brough, Ph.D. Chief Scientific Officer Safe Harbor Statement Statements herein

More information

Gene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University

Gene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University Gene Therapy: The Basics Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University Definition of gene therapy Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic

More information

Second Quarter 2016 Financial Results. August 4, 2016

Second Quarter 2016 Financial Results. August 4, 2016 Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking

More information

Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care

Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.

More information

Discovery of drugs and drug resistance. Model organisms. Plants and livestock. Cell-based disease modelling. Therapeutics

Discovery of drugs and drug resistance. Model organisms. Plants and livestock. Cell-based disease modelling. Therapeutics Genome editing for the engineering of cell lines and animal models Major applications are in: Discovery of drugs and drug resistance Model organisms Plants and livestock Cell-based disease modelling Therapeutics

More information

T-cell engineering for adoptive immunotherapy using TALeffector. Sophie Derniame PhD Project Leader, CellectisTherapeutics

T-cell engineering for adoptive immunotherapy using TALeffector. Sophie Derniame PhD Project Leader, CellectisTherapeutics T-cell engineering for adoptive immunotherapy using TALeffector nucleases (TALEN ) Sophie Derniame PhD Project Leader, CellectisTherapeutics FORWARD LOOKING STATEMENT This communication expressly or implicitly

More information

Course Agenda. Day One

Course Agenda. Day One Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an

More information

Antibody against Chikungunya virus (mrna-1944)

Antibody against Chikungunya virus (mrna-1944) Antibody against Chikungunya virus (mrna-1944) Modality Program # Program Indication Preclinical development Phase 1 Phase 2 Phase 3 and commercial Moderna rights mrna-1944 Antibody against Chikungunya

More information

Jefferies 2014 Global Healthcare Conference

Jefferies 2014 Global Healthcare Conference Jefferies 2014 Global Healthcare Conference Edward Lanphier President & CEO Sangamo BioSciences, Inc. June 5, 2014 Forward Looking Statements This presentation contains forward-looking statements within

More information

Precigen Company Update

Precigen Company Update Precigen Company Update Helen Sabzevari, PhD President, Precigen 9 January 2019 JP Morgan 37 th Annual Healthcare Conference Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation

More information

Jefferies 2016 Healthcare Conference Engineering Genetic Cures

Jefferies 2016 Healthcare Conference Engineering Genetic Cures Jefferies 2016 Healthcare Conference Engineering Genetic Cures Edward Lanphier Founder Sangamo BioSciences, Inc. June 8, 2016 Forward Looking Statements This presentation contains forward-looking statements

More information

Pros and Cons of Gene Therapy in ß-Thalassemia

Pros and Cons of Gene Therapy in ß-Thalassemia Pros and Cons of Gene Therapy in ß-Thalassemia ß-Thalassemia: established and potential new therapeutic approaches Many ß-thalassemic patients are treated with blood transfusion and iron chelation. However,

More information

ABOUT GLYCOSTEM. Company Overview

ABOUT GLYCOSTEM. Company Overview ABOUT GLYCOSTEM The company is a clinical stage biotech company established in the Netherlands in 2007. The company s headquarters and new state-of-the-art lab and production facilities are based at Pivot

More information

Regulatory Pathways for Rare Diseases

Regulatory Pathways for Rare Diseases Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case

More information

Making Hope A Reality bluebird style. November, 2017 Nasdaq : BLUE

Making Hope A Reality bluebird style. November, 2017 Nasdaq : BLUE Making Hope A Reality bluebird style November, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The

More information

Quality development considerations - Regulatory perspective

Quality development considerations - Regulatory perspective Quality development considerations - Regulatory perspective CAT workshop on cell-based immunotherapies, London 15. 11.2016 Christiane Niederlaender CAT Member, MHRA An agency of the European Union Genetically

More information

Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018

Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018 Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018 Rachel Witten, M.D. Medical Officer Office of Tissues and Advanced Therapies Center for

More information

GENERATION OF OFF-THE-SHELF TCR-LESS CAR T CELLS FROM RENEWABLE PLURIPOTENT CELLS

GENERATION OF OFF-THE-SHELF TCR-LESS CAR T CELLS FROM RENEWABLE PLURIPOTENT CELLS GENERATION OF OFF-THE-SHELF TCR-LESS CAR T CELLS FROM RENEWABLE PLURIPOTENT CELLS Bob Valamehr, PhD Vice President, Fate Therapeutics AACR Annual Meeting 2018 Press Program McCormick Place North/South

More information

Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017

Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017 Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017 Outline Products regulated Significance of complex biologics Product and process Cutting

More information

COMMITMENT TO A CURE. cellectis.com

COMMITMENT TO A CURE. cellectis.com COMMITMENT TO A CURE cellectis.com FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s current expectations and assumptions and on information

More information

First Quarter Trusted by the Life Sciences Industry

First Quarter Trusted by the Life Sciences Industry First Quarter 2018 Trusted by the Life Sciences Industry 1 Safe Harbor Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such

More information

Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks

Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks September 5, 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II

More information

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants

More information

INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

Precigen Company Update

Precigen Company Update Precigen Company Update Helen Sabzevari, PhD President, Precigen 7 January 2019 Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made

More information

GENE EDITED CAR-T THERAPIES THE PARADIGM IN ONCOLOGY

GENE EDITED CAR-T THERAPIES THE PARADIGM IN ONCOLOGY GENE EDITED CAR-T THERAPIES THE PARADIGM IN ONCOLOGY Cellectis, March 2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION CONTAINS FORWARD- LOOKING STATEMENTS THAT ARE BASED ON OUR MANAGEMENT S CURRENT

More information

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Cell and Gene Therapy Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Daniel Stark Head External Supply Cell- and Gene Therapies Development and Manufacturing

More information

Non-viral Delivery of ZFN mrna Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets

Non-viral Delivery of ZFN mrna Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets Non-viral Delivery of ZFN mrna Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets Anthony Conway, Ph.D. May 19, 2018 Outline Engineered zinc finger nuclease (ZFN) technology

More information

Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells

Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells David M, Hambly, Ph.D. Director, Analytical Development April 4th, 2016 Forward Looking Statements/Safe

More information

JUST THE FACTS 1. Nearly 300 Cell and Gene Therapies in Development for A Broad Range of Diseases

JUST THE FACTS 1. Nearly 300 Cell and Gene Therapies in Development for A Broad Range of Diseases TM TM MEDICINES IN DEVELOPMENT 018 REPORT CELL AND GENE THERAPIES JUST THE FACTS 1 5 DISEASES CURRENTLY TREATED WITH CELL AND GENE THERAPY MEDICINES IN DEVELOPMENT FOR CELL THERAPY AND GENE THERAPY Nearly

More information

Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)

Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs

More information

Current SCID Gene Transfer Experience

Current SCID Gene Transfer Experience Current Perspectives on Gene Transfer for X-SCID Recombinant DNA Advisory Committee Safety Symposium March 15, 2005 Discussion Questions Current SCID Gene Transfer Experience 1. What data is available

More information

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. Agios Pharmaceuticals, Inc. The people pictured here are some of the many friends and family of Agios employees affected by cancer. All of us at Agios are passionate about transforming patients lives.

More information

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy

More information

Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective

Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of

More information

Global Leader in Viral Vector Technologies

Global Leader in Viral Vector Technologies Global Leader in Viral Vector Technologies Gene Therapy Vaccines - Discovery 1 SIRION BIOTECH ANY GENE TO ANY CELL Expert for viral vectors Competitive proprietary viral vector platforms High-end enabling

More information

Results to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Results to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13 Amicus Therapeutics Announces Positive Results from All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease Strong Proof-of-Concept Data for Chaperone

More information

Research Xchange Forum 2018

Research Xchange Forum 2018 Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany What to expect Learn about the latest

More information

Welcome to the Webinar! Human Genome Editing: Latest Developments and Advancements

Welcome to the Webinar! Human Genome Editing: Latest Developments and Advancements Welcome to the Webinar! Human Genome Editing: Latest Developments and Advancements Thursday, February 22, 2018 at 10:30am PT/1:30pm ET Co-hosted by: The National Academy of Sciences (NAS) and the National

More information

Hemophilia and Gene Therapy

Hemophilia and Gene Therapy Hemophilia and Gene Therapy Jackie Chu June 4, 2008 Overview Hemophilia, the disease Gene therapy Hemophilia as a target for gene therapy Gene delivery systems Clinical trials New methods Future of gene

More information

Press Release. Interim Data Summary

Press Release. Interim Data Summary Print Page Close Window Press Release bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D at AAN 2016 Annual Meeting First clinical data to be presented from Phase 2/3 Starbeam Study;

More information

Stem Cells Regenerative Medicine Congress September 15, 2014

Stem Cells Regenerative Medicine Congress September 15, 2014 Stem Cells Regenerative Medicine Congress 2014 September 15, 2014 Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use

More information

Cell and gene therapy: scaling up and moving to mass production

Cell and gene therapy: scaling up and moving to mass production EDITORIAL Cell and gene therapy: scaling up and moving to mass production Nigel Whittle In order to fulfil the promise of cell therapy, it is important that manufacture of these therapies can be industrialized

More information

SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)

SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Corporate Presentation. April 2016

Corporate Presentation. April 2016 Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Good morning and thank you for joining us for our quarterly update.

Good morning and thank you for joining us for our quarterly update. Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have

More information

About Sarepta Therapeutics

About Sarepta Therapeutics Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply -- The partnership will provide commercial supply

More information

Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications

Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning

More information

Advancing Manufacturing for Advanced Therapies

Advancing Manufacturing for Advanced Therapies Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products

More information

Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017

Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017 Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical

More information

KNOW HOW & TECHNOLOGY LICENSING OPPORTUNITIES

KNOW HOW & TECHNOLOGY LICENSING OPPORTUNITIES Vector platform developed at SAN RAFFAELE TELETHON INSTITUTE FOR GENE THERAPY SAN RAFFAELE HOSPITAL AND SCIENTIFIC INSTITUTE KNOW HOW & TECHNOLOGY LICENSING OPPORTUNITIES -regulated vectors and their uses

More information

ENGINEERED CAR-T THERAPIES

ENGINEERED CAR-T THERAPIES ENGINEERED CAR-T THERAPIES A NEW PARADIGM IN ONCOLOGY FEBRUARY 2017 2 FORWARD LOOKING STATEMENTS THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON OUR MANAGEMENT S CURRENT EXPECTATIONS

More information

Cellular Therapy Product

Cellular Therapy Product Cellular Therapy Product Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 4003 revision 1 (page 1 of 7). Last Updated January, 2018. Cellular Therapy

More information

-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise --

-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise -- Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies -- Sarepta

More information

Orchard Therapeutics. Overcoming the complex challenges associated with ex vivo gene therapies. Adrien Lemoine VP Business Development & Operations

Orchard Therapeutics. Overcoming the complex challenges associated with ex vivo gene therapies. Adrien Lemoine VP Business Development & Operations Orchard Therapeutics Overcoming the complex challenges associated with ex vivo gene therapies Adrien Lemoine VP Business Development & Operations Orchard at a glance Who we are Our mission Team Academic

More information

Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc. Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions

More information

BioCentury Future Leaders Conference. March 20, 2015

BioCentury Future Leaders Conference. March 20, 2015 BioCentury Future Leaders Conference March 20, 2015 Forward Looking Statement This presentation includes certain estimates and other forward-looking statements within the meaning of Section 21E of the

More information

SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December

More information

NEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies

NEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies NEXT-GENERATION CAR T-CELLS AGAINST CANCER Gene-Edited Off-The-Shelf Immunotherapies Forward-looking Statements This presentation contains forward-looking statements that are based on our management s

More information

Spark Therapeutics, Inc.

Spark Therapeutics, Inc. Spark Therapeutics, Inc. Corporate Overview August 2018 1 Forward looking statements This presentation contains "forward looking statements" within the meaning of the Private Securities Litigation Reform

More information

Global Gene Therapy Market Report -2026

Global Gene Therapy Market Report -2026 Global Gene Therapy Market Report -2026 July 2018 Table of Contents 1 Executive Summary 2 Gene Therapy: Overview Viral Vectors for Gene Therapy Viral Vectors Non-Viral Vectors Types of Gene Therapy Somatic

More information

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat

More information

Loxo Oncology Announces Third Quarter 2016 Financial Results

Loxo Oncology Announces Third Quarter 2016 Financial Results Loxo Oncology Announces Third Quarter 2016 Financial Results November 2, 2016 Updated LOXO-101 Phase 1 Clinical Data Accepted for Oral Presentation at ESMO Asia on December 18, 2016 Company to Provide

More information

Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis

Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF

More information

From regulation to reality challenges in translation of gene therapy and cell-based medicinal products

From regulation to reality challenges in translation of gene therapy and cell-based medicinal products From regulation to reality challenges in translation of gene therapy and cell-based medicinal products Gene therapy case study: ADA-SCID Alessandro Aiuti Jonathan Appleby HSR-TIGET is focused on the implementation

More information

ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES

ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular

More information

Company Presentation June 2016

Company Presentation June 2016 Company Presentation June 2016 Legal Disclaimers This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. All statements contained

More information

Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products

Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT

More information

Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018

Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018 Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells Cell Therapy Liaison Meeting January, 2018 Outline Development of the Cellular Therapy Registry Standardized Data

More information

Regulatory requirements for cell based medicinal products

Regulatory requirements for cell based medicinal products Regulatory requirements for cell based medicinal products 資料 3-2 Committee 25 August 2010 Dr. Bettina Klug, MSc Paul-Ehrlich-Institut, Langen klube@pei.de Paul-Ehrlich-Institut Federal Institute for Vaccines

More information

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018 Medical Topics: Gene Therapy E. Anne Jackson, FSA MAAA July 30, 2018 Agenda Terminology Crash course in the science Existing FDA-approved gene therapies Underwriting implications 2 Terms related to high

More information